Work as C&Q Document Preparation Support at Amgen
1 July 2026

Work as C&Q Document Preparation Support at Amgen

Amgen is seeking a Senior Associate specializing in Commissioning & Qualification (C&Q) to join the Engineering C&Q Center of Excellence (CoE). In this role, you will support the preparation, coordination, and delivery of commissioning and qualification lifecycle documentation supporting engineering projects and GMP manufacturing systems across Amgen operations.
Quality Assurance Jobs at BioMatrix Healthcare
1 July 2026
Quality Assurance Jobs at BioMatrix Healthcare
The candidate should have hands-on experience in Change Control, Deviations, CAPA management, CAPA Closure, and overall QMS activities.
Scientists Transform Human Cells into Living Biocomputers, Opening New Path for Precision Cancer Therapy
1 July 2026
Scientists Transform Human Cells into Living Biocomputers, Opening New Path for Precision Cancer Therapy
Researchers at the Hebrew University of Jerusalem have developed an innovative genetic programming system that enables human cells to process information and make autonomous decisions, functioning much like miniature biological computers.
AbbVie’s Chemotherapy-Free Lymphoma Regimen Achieves Major Phase 3 Success, Significantly Delaying Disease Progression
1 July 2026
AbbVie’s Chemotherapy-Free Lymphoma Regimen Achieves Major Phase 3 Success, Significantly Delaying Disease Progression
AbbVie has announced positive topline results from the Phase 3 EPCORE DLBCL-4 clinical trial, demonstrating that a chemotherapy-free combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) in adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) compared with the current standard-of-care regimen.
FDA Approves Tregzi, First Regulatory T-Cell Therapy to Reduce Chronic GVHD After Stem Cell Transplant
1 July 2026
FDA Approves Tregzi, First Regulatory T-Cell Therapy to Reduce Chronic GVHD After Stem Cell Transplant

The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).